CRP/Alb比值对肺癌患者预后的临床价值

摘要

Objective To evaluate C-reactive protein(CRP)/albumin(Alb) ratio in the prognosis of lung cancer. Methods The clinical and laboratory data of 121 patients with lung cancer were recorded retrospectively. Neutrophil/lymphocyte ratio (NLR),platelet/lymphocyte ratio (PLR),systemic immune-inflammation index (SII),Glasgow prognostic score (GPS) and CRP/Alb ratio were determined before chemotherapy or surgery, and the results were analyzed statistically. Results There was no statistical significance for survival time between different pathological types and between carcinoembryonic antigen(CEA) normal and abnormal groups (P>0.05). The survival time of males was shorter than that of females(P<0.05),and the survival time of CRP or Alb abnormal group was shorter than that of CRP or Alb normal group (P<0.05). There was no statistical significance for survival time among NLR,PLR and SII normal and abnormal groups (P>0.05),while the survival time of GPS 0 group was longer than those of GPS 1 and GPS 2 groups (P<0.05). The survival time of CRP/Alb ratio normal group was longer than that of CRP/Alb ratio abnormal group (P<0.01). CRP/Alb ratio in different pathological types and clinical stages had no statistical significance (P>0.05). Conclusions CRP/Alb ratio may be a prognostic indicator for lung cancer,independently to pathological types and clinical stages. High CRP/Alb ratio suggests a poor prognosis.%目的 评估C反应蛋白(CRP)/白蛋白(Alb)比值在预测肺癌患者预后中的临床价值.方法 随访记录121例肺癌患者的生存期和实验室指标,在化疗或手术前检测中性粒细胞/淋巴细胞比值(NLR)、血小板/淋巴细胞比值(PLR)、全身免疫炎症指数(SII)、格拉斯哥预后评分(GPS)和CRP/Alb比值,并对检测结果进行统计分析.结果 肺癌不同病理类型之间及癌胚抗原(CEA)正常组与异常组之间生存期差异无统计学意义(P>0.05).男性肺癌患者生存期明显短于女性(P<0.05),CRP或Alb异常组生存期明显短于CRP或Alb正常组(P<0.05).NLR、PLR、SII正常组与异常组生存期差异无统计学意义(P>0.05),而GPS 0分组的生存期明显长于GPS 1分组和GPS 2分组(P<0.05),CRP/Alb比值正常组生存期明显长于异常组(P<0.01);不同病理类型和临床分期患者的CRP/Alb比值差异无统计学意义(P>0.05).结论 CRP/Alb比值可能是独立于病理类型和临床分期的肺癌预后指标,CRP/Alb比值高提示预后不良.